PDGFRA has demonstrated its potential as a therapeutic target for gastrointestinal stromal tumours (Theiss and Contreras, 2019) and these studies are consistent with the results of our study which suggest that the increased expression of these genes improves the survival potential of patients in Ras-cluster 3. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.